US Proposes Restrictions on Chinese Biotech Investments
Article Content
- •The US Treasury's proposed rule restricts investments in Chinese biotech under the COINS Act.
- •The rule prohibits financial transactions with Chinese biotech companies, affecting future collaborations.
- •US drugmakers can still buy rights to Chinese-developed medicines despite the new restrictions.
On October 23, 2026, the US Treasury Department proposed a rule under the COINS Act that would impose significant restrictions on US investments in the Chinese biotech sector. This rule adds biotechnology to a list of industries deemed sensitive to national security, which already includes semiconductors and AI. The proposal prohibits US companies from engaging in financial transactions with Chinese biotech firms or manufacturers of related equipment. While American drugmakers can still acquire rights to medicines developed in China, the new restrictions are expected to dramatically impact ongoing and future partnerships. The biotech industry, which has seen a surge of deals between the US and China in recent years, is now bracing for a lobbying effort to influence the rule's final form. The announcement has sparked discussions about the potential ramifications for innovation and collaboration in the biotech field.
Ask AI about this cluster
Answers cite the sources they use